June 2017 Issue of MMM
Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
MM&M Hall of Femme
For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.
Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family ...
In apportioning their media budgets, pharma companies continue to straddle the line between new and traditional strategies.
A trio of industry leaders counsels on numerous HUB strategies that will help providers vastly improve the patient experience.
Along with lower costs, effective co-pay offset programs boost patient adherence and better connect with doctors and pharmacies.
Amidst the massive technological and social changes upending the societal status quo, the culture of doctors around the globe is also in flux. Technology must ...
To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Beset by high prices and scientific complexity, how can marketers best communicate the value of specialty drugs?
The president of the 2017 Lions Health pharma jury shares campaigns that incorporate technology, innovation, and creative thinking to impact behaviors and change lives.
Healthcare marketing has a head start in grooming women leaders. But it's by no means a fait accompli.